346 related articles for article (PubMed ID: 8573424)
1. Therapeutic strategy in Paget's disease of bone.
Meunier PJ; Vignot E
Bone; 1995 Nov; 17(5 Suppl):489S-491S. PubMed ID: 8573424
[TBL] [Abstract][Full Text] [Related]
2. [Paget's disease and its therapeutic management].
Orcel P; Rousière M
Presse Med; 2005 Apr; 34(8):612-6. PubMed ID: 15962504
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
4. The methodology of clinical trials of oral tiludronate in Paget's disease of bone.
Roux C
Bone; 1995 Nov; 17(5 Suppl):497S-499S. PubMed ID: 8573426
[TBL] [Abstract][Full Text] [Related]
5. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.
Harinck HI; Bijvoet OL; Blanksma HJ; Dahlinghaus-Nienhuys PJ
Clin Orthop Relat Res; 1987 Apr; (217):79-98. PubMed ID: 2951049
[TBL] [Abstract][Full Text] [Related]
6. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
8. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
9. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
[TBL] [Abstract][Full Text] [Related]
11. Two cases of monostotic Paget's disease: effects of bisphosphonate.
Hoshiro M; Harada T; Iwai H; Miyatake T; Nishimura A; Ohno Y; Aoki N
Endocr J; 2003 Aug; 50(4):385-92. PubMed ID: 14599111
[TBL] [Abstract][Full Text] [Related]
12. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC
Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy of Paget's disease of bone with EHDP.
Siris ES; Canfield RE; Jacobs TP; Baquiran DC
Arthritis Rheum; 1980 Oct; 23(10):1177-84. PubMed ID: 6775644
[TBL] [Abstract][Full Text] [Related]
14. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
15. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
Wimalawansa SJ; Gunasekera RD
Calcif Tissue Int; 1993 Oct; 53(4):237-41. PubMed ID: 8275351
[TBL] [Abstract][Full Text] [Related]
16. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.
Yates AJ; Percival RC; Gray RE; Atkins RM; Urwin GH; Hamdy NA; Preston CJ; Beneton MN; Russell RG; Kanis JA
Lancet; 1985 Jun; 1(8444):1474-7. PubMed ID: 2861411
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
Reid IR; Nicholson GC; Weinstein RS; Hosking DJ; Cundy T; Kotowicz MA; Murphy WA; Yeap S; Dufresne S; Lombardi A; Musliner TA; Thompson DE; Yates AJ
Am J Med; 1996 Oct; 101(4):341-8. PubMed ID: 8873503
[TBL] [Abstract][Full Text] [Related]
18. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed.
Filipponi P; Pedetti M; Beghe F; Giovagnini B; Miam M; Cristallini S
Bone; 1994; 15(3):261-7. PubMed ID: 8068446
[TBL] [Abstract][Full Text] [Related]
19. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
Whitson HE; Lobaugh B; Lyles KW
Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
